Welcome to our dedicated page for Immunovant SEC filings (Ticker: IMVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immunovant, Inc. (Nasdaq: IMVT) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing a structured view into its operations as a clinical-stage immunology company. These documents complement Immunovant’s focus on developing FcRn-targeting monoclonal antibodies, including IMVT-1402 and batoclimab, for IgG-mediated autoimmune diseases.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q, where Immunovant discusses research and development activities, general and administrative expenses, net losses and cash balances. These filings also describe the company’s single operating segment, risk factors related to clinical development and financing needs, and its relationship with controlling stockholder Roivant Sciences Ltd.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings have addressed quarterly financial results, leadership changes, executive employment agreements, separation arrangements with senior officers, clinical program updates in Graves’ disease and other indications, and outcomes of the company’s annual meeting of stockholders. These filings can include or reference press releases with detailed clinical and financial information.
Immunovant’s proxy statements on Schedule 14A offer insight into corporate governance, board composition, executive compensation and stockholder voting matters. The definitive proxy statement also outlines the company’s corporate history, including its business combination that resulted in the current Immunovant, Inc. structure.
Through Stock Titan, users can access these SEC filings as they are made available on EDGAR, along with AI-powered summaries that help explain key points in lengthy documents. This includes highlighting major changes in clinical strategy, financing transactions, governance decisions and other disclosures that shape the risk and opportunity profile for IMVT.
Immunovant, Inc. Chief Financial Officer Tiago Girao reported an open-market sale of 25,760 shares of common stock at a weighted average price of $29.62 per share. After this transaction, he directly holds 247,596 shares.
According to the footnotes, this sale was executed solely to cover tax withholding obligations tied to the vesting and settlement of 52,097 restricted stock units from a prior grant of 208,388 RSUs. The company required a “sell to cover” transaction, so the sale is described as non-discretionary for the executive.
Immunovant, Inc. Chief Technology Officer Jay S. Stout reported an open-market sale of 2,754 shares of common stock at a weighted average price of $29.62 per share. According to the footnotes, these shares were sold solely to cover tax withholding obligations from the vesting of previously granted RSUs.
The sale was mandated by the company’s “sell to cover” election and is described as not a discretionary transaction by the executive. Following the sale, Stout directly owns 251,685 shares of Immunovant common stock.
Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl reported an open-market sale of 5,165 shares of common stock on April 8, 2026 at a weighted average price of $24.83 per share. According to the disclosure, this sale was required to cover tax withholding obligations tied to the vesting and settlement of previously granted restricted stock units and was not a discretionary trade. Following the transaction, Van Tuyl directly holds 183,231 shares of Immunovant common stock.
Immunovant, Inc. Chief Operating Officer Gloria Melanie reported an open-market sale of 8,722 shares of common stock at a weighted average price of $24.83 per share. According to the filing, this sale was mandated as a “sell to cover” transaction to satisfy tax withholding obligations from the vesting and settlement of previously granted restricted stock units. On April 1, 2025, she was granted 76,181 RSUs, of which 19,045 RSUs vested on April 1, 2026. Following the sale, she directly holds 245,222 shares of Immunovant common stock.
Immunovant, Inc. Chief Technology Officer Jay S. Stout reported selling a total of 10,132 shares of common stock on April 8, 2026, at a weighted average price of $24.83 per share. According to the footnotes, these sales were mandated "sell to cover" transactions to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units.
The filing states that part of the sale related to 19,045 RSUs that vested on April 1, 2026, from a 76,181-RSU grant made on April 1, 2025, and part related to 3,436 RSUs that vested on April 2, 2026, from a 54,978-RSU grant made on April 2, 2024. After these transactions, Stout directly holds 254,439 shares of Immunovant common stock.
Immunovant, Inc. director Frank Torti reported equity awards consisting of stock options and restricted stock units as part of his compensation. He received options for 88,325 shares of common stock at an exercise price of $24.61 per share, expiring in 2036. He was also granted 174,189 restricted stock units (RSUs), each representing one share of common stock upon vesting. Both the options and RSUs vest in substantially equal quarterly installments over two years starting from April 1, 2026, contingent on his continuous service. Following the common stock award, he directly holds 1,009,228 shares of Immunovant common stock.
Immunovant, Inc. director Andrew J. Fromkin received equity compensation on April 7, 2026. He was granted 13,880 restricted stock units under the 2019 Equity Incentive Plan, with each RSU representing one share of common stock upon vesting.
He was also granted stock options for 7,061 shares of common stock at an exercise price of $24.61 per share, expiring April 7, 2036. Both the RSUs and options vest in full on April 1, 2027, subject to his continuous service. Following the RSU grant, he holds 99,732 shares of common stock directly, and the RSUs may be settled later if he elects deferral under Rule 409A.
Immunovant, Inc. reported that director Douglas J. Hughes received new equity awards as part of his compensation. He was granted 13,880 shares of Common Stock in the form of restricted stock units, bringing his direct holdings to 134,653 common shares after the grant.
He also received a stock option covering 7,061 shares of Common Stock at an exercise price of $24.61 per share. Both the RSUs and the option awards vest in full on April 1, 2027, subject to his continuous service with the company, and the options expire on April 7, 2036. The RSUs may be settled later at his election, subject to Rule 409A.
Immunovant, Inc. director Atul Pande received new equity awards as part of his compensation. He was granted stock options for 7,061 shares of common stock at an exercise price of $24.61 per share, expiring on April 7, 2036. He also received 13,880 shares of common stock in the form of restricted stock units. These RSUs and the option shares will vest on April 1, 2027, if he continues service with the company through that date. Following these awards, he holds 116,731 common shares directly and 20,000 common shares indirectly through a trust.
Immunovant, Inc. director Jake Bauer reported receiving new equity awards as part of his compensation. On April 7, 2026 he was granted 13,880 shares of Common Stock in the form of restricted stock units under the company’s 2019 Equity Incentive Plan. These RSUs vest in full on April 1, 2027, conditional on his continuous service, and each unit converts into one share, with an option to defer settlement under Rule 409A. He also received a stock option for 7,061 shares at an exercise price of $24.61 per share, expiring April 7, 2036, which will vest on April 1, 2027 on the same service condition. Following the stock grant, he directly owns 38,896 shares of Immunovant common stock.